Back

Estimated glomerular filtration rate trajectories by transthyretin stabilisation status in ATTR-ACT

30 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Heart failure redefined: hypertrophic cardiomyopathy and transthyretin amyloid cardiomyopathy precision treatments Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Stefano Perlini

University of Pavia, Pavia (Italy)

6 More presentations in this session

Presentation thumbnail
Fewer adverse events reported in ATTR-CM patients treated with vutrisiran versus placebo: Post hoc safety analysis from HELIOS-B
Doctor S. Schwarting (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Building on the demonstrated functional benefit of tafamidis: association of TTR stabilisation with 6MWT outcomes in ATTR ACT
Associate Professor M. Crespo-Leiro (A Coruna, ES)
Abstract Slides Video
Presentation thumbnail
Long-term efficacy of vutrisiran in patients with variant transthyretin amyloid cardiomyopathy
Doctor T. Zaizen (Oita, JP)
Abstract Slides
Presentation thumbnail
Comprehensive assessment of disease status in ATTRwt-CM: Integrating serum transthyretin levels with clinical parameters using stabilizer therapy
Assistant Professor K. Yoshie (Matsumoto, JP)
Abstract Slides
Presentation thumbnail
The importance of distinct cardiac MRI regional analyses to assess the effects of cliramitug on amyloid depletion from the Phase 1b study NI006-101
Doctor F. Aus Dem Siepen (Heidelberg, DE)
Abstract Slides

Access the full session

Session thumbnail
Heart failure redefined: hypertrophic cardiomyopathy and transthyretin amyloid cardiomyopathy precision treatments

The Event

Event poster

ESC Congress 2026

30 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Relationship between changes in renal function after acute phase of tafamidis administration and left ventricular diastolic function at mid-term follow-up in transthyretin cardiac amyloidosis
31 August 2024
thumbnail
Congress Presentation
Impacts of RAS and renal perfusion on eGFR in hypertensive patients, independent of renal artery stenosis
1 September 2025
thumbnail
Congress Presentation
Finerenone in patients with heart failure and deterioration in eGFR to <25ml/min/1.73m2 in the FINEARTS-HF Trial
17 May 2025
thumbnail
Congress Presentation
Determinants of circulating transthyretin levels across the clinical spectrum of transthyretin amyloidosis
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources